CLEAR-AS: CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis

NCT07469371 · tracked via the Priya Life Science China tracker

Sponsor

Yan'an Affiliated Hospital of Kunming Medical University

Phase

Not applicable

Started

2026-04-01

Last updated

2026-04-16

Condition(s) studied

Severe Aortic Stenosis

Investigational drug(s) / intervention(s)

CCTA plus CT-FFR-informed preoperative decision strategyCCTA-guided preoperative decision strategy

CCTA plus CT-FFR-informed preoperative decision strategy: Preoperative coronary evaluation and revascularization decision-making before aortic valve replacement are based on combined CCTA anatomical assessment and CT-FFR functional assessment. When anatomical and functional assessments are concordant, both are considered in treatment planning. When anatomical and functional assessments are discordant, the CT-FFR functional result serves as the primary basis for revascularization decision-making.

CCTA-guided preoperative decision strategy: CCTA is performed as the standardized preoperative anatomic coronary assessment in patients with severe aortic stenosis scheduled for aortic valve replacement. Coronary stenosis is evaluated by 2 experienced radiologists using the 18-segment coronary model, visual diameter stenosis assessment, and CAD-RADS 2.0 classification. In the control strategy, coronary evaluation and revascularization planning are based on CCTA anatomic findings alone.

Study summary

Severe aortic stenosis (AS) is often accompanied by coronary artery disease (CAD). While coronary computed tomography angiography (CCTA) is routinely used before aortic valve replacement (AVR) to evaluate coronary anatomy, it lacks physiological assessment of myocardial ischemia.

This prospective, single-center, randomized controlled trial aims to evaluate whether integrating functional assessment using CT-derived fractional flow reserve (CT-FFR) with CCTA can optimize revascularization decision-making and improve clinical outcomes. A total of 300 severe AS patients scheduled for transcatheter or surgical AVR will be randomly assigned to either the experimental group (revascularization decisions guided by both CCTA and CT-FFR) or the control group (decisions guided by CCTA alone). Participants will be followed up for 1 year to assess major adverse cardiovascular events and other clinical outcomes.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Age \>18 years. 2. Severe aortic stenosis confirmed by echocardiography, defined as peak aortic jet velocity (Vmax) ≥4.0 m/s, mean transvalvular gradient ≥40 mmHg, or aortic valve area (AVA) ≤1.0 cm² \[or indexed aortic valve area (AVAi) ≤0.6 cm²/m²\]. 3. New York Heart Association (NYHA) functional class II or higher. 4. Eligible for both transfemoral transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). 5. Undergoing preoperative coronary computed tomography angiography (CCTA). 6. Willing to participate in the study and able to provide written informed consent. Exclusion Criteria: 1. Allergy to prosthetic valve materials or iodinated contrast agents. 2. Contraindication or allergic reaction to anticoagulants or antiplatelet agents, or inability to tolerate required anticoagulant or antiplatelet therapy. 3. Active infective endocarditis or any other active infection. 4. Severe vascular disease precluding safe implantation of a prosthetic valve. 5. Ascending aortic diameter ≥50 mm. 6. Prior prosthetic valve implantation in any cardiac position or prior coronary artery bypass grafting (CABG). 7. Preoperative imaging confirming aortic root anatomy unsuitable for transcatheter aortic valve implantation. 8. Intracardiac mass, left ventricular or left atrial thrombus, or vegetation confirmed by preoperative echocardiography. 9. Acute myocardial infarction within 30 days before surgery. 10. Clinically diagnosed stroke or transient ischemic attack within 3 months before surgery. 11. Bleeding or coagulation disorders within 3 months before surgery that required hospitalization or blood transfusion or were otherwise clinically significant and would preclude the antiplatelet therapy required in this study.

Primary outcome measure(s)

Major Adverse Cardiovascular Events (MACE) — At 1 year (365 days) post-AVR
The primary endpoint is a cardiovascular-focused composite including major adverse cardiovascular events (MACE, defined as cardiac death, nonfatal myocardial infarction, unstable angina, heart failure admission, clinically-driven target vessel revascularization, or valve re-intervention). This outcome will be reported as the percentage of participants experiencing at least one of these events.

Trial sites (1)

Facility	City	Region	Status
Yan'an Hospital Affiliated to Kunming Medical University	Kunming	Yunnan	Recruiting

More Yan'an Affiliated Hospital of Kunming Medical University trials in China

Safety and Efficacy of TEVAR Combined With Long Bare-metal Stents in the Intervention of ATBAD Starting soon

A Study on the Correlation Between Cardiac-Cerebral Oxygenation Reserve and Cognitive Function Changes in Heart Failure Patients Enrolling by invitation

Other trials for the same condition

Safety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis Recruiting

A Prospective, Multicenter, Single-arm Study to Evaluate a Transcatheter Aortic Valve System Safety and Efficacy for the Treatment of Patients With Severe Aortic Stenosis Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07469371 on ClinicalTrials.gov ↗ ← All trials in China